

1 **Title: Testing and Validation of Reciprocating Positive Displacement Pump for**
2 **Benchtop Pulsating Flow Model of Cerebrospinal Fluid Production and Other Physiologic**
3 **Systems**

4
5 **Authors: Ahmad Faryami¹, Adam Menkara¹, Daniel Viar², Dr. Carolyn A Harris³**

6 1 Department of Biomedical Engineering, Wayne State University, Detroit, MI 48202

7 2 Department of Computer Science and Engineering, University of Toledo, Toledo, Ohio,
8 43606

9 3 Carolyn A Harris, Ph.D. (corresponding author), Wayne State University Dept. of
10 Chemical Engineering and Materials Science, 6135 Woodward Avenue, Rm 3120,
11 Detroit, MI 48202

12 **Abstract**

13 Background: The flow of physiologic fluids through organs and organs systems is an integral
14 component of their function. The complex fluid dynamics in many organ systems are still not
15 completely understood, and in-vivo measurements of flow rates and pressure provide a testament
16 to the complexity of each flow system. Variability in in-vivo measurements and the lack of
17 control over flow characteristics leave a lot to be desired for testing and evaluation of current
18 modes of treatments as well as future innovations. In-vitro models are particularly ideal for
19 studying neurological conditions such as hydrocephalus due to their complex pathophysiology
20 and interactions with therapeutic measures. The following aims to present the reciprocating
21 positive displacement pump, capable of inducing pulsating flow of a defined volume at a
22 controlled beat rate and amplitude. While the other fluidic applications of the pump are currently
23 under investigation, this study was focused on simulating the pulsating cerebrospinal fluid
24 production across profiles with varying parameters.

25 Methods: Pumps were manufactured using 3D printed and injection molded parts. The pumps
26 were powered by an Arduino-based board and proprietary software that controls the linear
27 motion of the pumps to achieve the specified output rate at the desired pulsation rate and
28 amplitude. A range of $0.01 \frac{ml}{min}$ to $0.7 \frac{ml}{min}$ was tested to evaluate the versatility of the pumps. The
29 accuracy and precision of the pumps' output were evaluated by obtaining a total of 150 one-
30 minute weight measurements of degassed deionized water per output rate across 15 pump
31 channels. In addition, nine experiments were performed to evaluate the pumps' control over
32 pulsation rate and amplitude.

33 Results: volumetric analysis of a total of 1200 readings determined that the pumps achieved the
34 target output volume rate with a mean absolute error of $-0.001034283 \frac{ml}{min}$ across the specified
35 domain. It was also determined that the pumps can maintain pulsatile flow at a user-specified beat rate
36 and amplitude.

37 Conclusion: The validation of this reciprocating positive displacement pump system allows for
38 the future validation of novel designs to components used to treat hydrocephalus and other
39 physiologic models involving pulsatile flow. Based on the promising results of these experiments
40 at simulating pulsatile CSF flow, a benchtop model of human CSF production and distribution
41 could be achieved through the incorporation of a chamber system and a compliance component.

42

43 **Keywords**

44 Hydrocephalus, In vitro modeling, Cerebrospinal fluid flow pattern, CSF dynamics, Microfluidic
45 pump, CSF amplitude

46 **Background**

47 Hydrocephalus describes a variety of conditions often presented with similar clinical symptoms.
48 The classic presentation of hydrocephalus involves elevated intracranial pressure (ICP) which
49 manifests with clinical symptoms such as severe headaches, visual problems, vomiting, loss of
50 consciousness, and in extreme cases if left untreated, coma and death. Although the first
51 experimental studies on hydrocephalus were conducted more than a century ago, the underlying
52 mechanisms are still an active area of research [1–4].

53 Cerebrospinal fluid (CSF) is a blood filtrate and is 99% composed of water. CSF also contains
54 important serum proteins such as fibrin, fibrinogen, IgG, and albumin [5]. Other than sharing
55 biochemistry with the cerebral vasculature, flow-sensitive magnetic resonance imaging has
56 demonstrated that CSF flow within the ventricles follows similar pulsatile flow dynamics. It is
57 also hypothesized that an increase in intraventricular pulsations occurs as the result of changes in
58 intracranial compliance. Many factors have been suggested to have an impact on intracranial
59 compliance, which also determines ICP dynamics in the patient cranium [6–8].

60 While overproduction of CSF may result in an increase in ICP and hydrocephalus manifestation,
61 reduction or obstruction in CSF removal and reabsorption hydrocephalus is another common
62 pathway for the pathologic manifestation[2,4]. Another imperative difference between
63 hydrocephalus patients is the length of time for hydrocephalus to develop and appear clinically.
64 The clinical appearance of hydrocephalus is easily apparent in neonatal patients which involve a
65 precipitous increase in head circumference while the pathology of hydrocephalus might take
66 significantly longer to appear in adult patients. In some instances, the gradual progression of the
67 disease allows that the intracranial compliance to adapt to the underlying causes of
68 hydrocephalus rendering no clinical presentations, symptoms, or high ICP for a long time which
69 may present clinically later in the patients' life [9–11]. Recent studies indicate that idiopathic
70 normal pressure hydrocephalus might be more common than it was previously supposed: new
71 evidence suggests it appears in 5.9% of individuals older than 80 years. Studies also suggest that
72 normal pressure hydrocephalus is underdiagnosed and undertreated due to its pathophysiology
73 that might expand over a few decades with similarities to diseases such as Alzheimer's and
74 dementia. It is estimated that 3.4 per 100,000 adults undergo a surgical procedure for

75 hydrocephalus with normal pressure hydrocephalus, high-pressure hydrocephalus, and aqueduct
76 stenosis accounting for 47, 27, and 15 percent of the patients respectively [12].

77 Shunt insertion is currently the most prevalent mode of treatment for the hydrocephalic
78 patient[13]. Nearly all patients, 98 percent, that received shunt placement therapy will experience
79 shunt failure which involves subsequent revision surgeries, incurring up to 1\$ billion in cost for
80 hydrocephalus care [14]. Therefore, hydrocephalus diagnosis and estimation of shunt success
81 rate for patients are among the most prolific fields of study. Flow sensitive magnetic resonance
82 imaging is one of the diagnostic tools that has been utilized to diagnose and evaluate shunt
83 success rates in patients. However, some of these methods are less accurate across various
84 patient cohorts. In situ, Magnetic Resonance (MR) measurements are resource and time-
85 intensive [15–17]. Furthermore, certain shunt systems have limited MR compatibility that could
86 further restrict access to post-surgery MR measurements.

87 Alternatively, animal studies are often used to investigate CSF dynamics and to provide insights
88 into the healthy and pathological conditions of living organisms. However, limitations of in-vivo
89 measurements, dramatic differences between humans and animals, and the lack of control over
90 flow dynamics leave a clear need for testing and evaluation of current modes of treatments [18].
91 Furthermore, simulating CSF production rate, pulsations and amplitudes might provide valuable
92 insights into the healthy and diseased states with significant diagnostic potential.

93 Due to its unique anatomy and function, up to 15 percent of the cardiac output is supplied to the
94 brain during the systole cycle and cranial blood flow and CSF are closely associated [19].

95 Particle tracing also demonstrated that the fluid dynamics and interactions between the
96 microvasculature and CSF spaces are complex and region-specific [20]. One of the advantages of
97 this pump is the capability to induce microfluidic flow rates at the physiologic beat rate and
98 amplitude directly, negating the need to modify the system or fluid pathway to achieve a variety
99 of flow patterns.

100 The main challenge of studying the fluid dynamics of hydrocephalus in a benchtop model is the
101 complex and diverse pathology of the underlying causes that present similar clinical symptoms.
102 Therefore, the pump must be capable of inducing pulsatile flow over a range of flow rates with
103 accurate control over beat rate and amplitude.

104 **Materials and Methods**

105 **Reciprocating Positive Displacement Pump**

106 Pumps are comprised of five syringes, 3D printed parts, a stepper motor, a stepper motor
107 coupler, a lead screw, linear bearings, and a series of check valves. Figure 2 illustrates a fully
108 assembled pump. Flow into and out of the syringes is through silicone tubes. Luer taper fittings
109 were used to establish fluid connections between all the components. The 3D printed parts were
110 manufactured using Anycubic I3 Mega printer using polylactic acid plastic (Anycubic
111 Technology CO., Limited, HongKong). The stepper motor, the motor coupler, and the lead screw
112 (composing a “drive unit”) are controlled by an Arduino-based board connected to a computer
113 with proprietary custom-built software built using Python that determines the rotation duration
114 and speed depending on the user-specified profile.

115 A user interface was developed to improve the user experience such that the pump output bulk
116 volume rate, beat rate, and amplitude can be easily input and modified as a function of time. The
117 rotational motion of the stepper motor is converted into linear actuation via the lead screw and
118 linear rods and bearings. A series of check-valves are placed immediately after the syringes to
119 allow exact volume output on the forward stroke and automatic refill on the backward motion.
120 Each board has a capacity for up to three separate pumps for a total of fifteen channels per
121 device.

122 Previously, peristaltic pumps were used to induce pulsating flow for bioreactor applications.
123 Operators such as Flow Limiting Operator were able to successfully control the peristaltic pump
124 output by controlling the motor rotations per minute. Inherently, peristaltic pump output and
125 pulse rate are locked together with dependence on tubing diameter [21]. One of the main
126 enhancements of this pump over previous designs is its capability to maintain a constant volume
127 rate at various beat rates and amplitude.

128 **Data Acquisition**

129 Flow patterns were obtained using six Sensirion SLF04 and SLF06 series flow sensors
130 (Sensirion AG, Switzerland). The flow data were acquired using Sensirion USB Sensor Viewer
131 software on a Hewlett-Packard desktop computer running Windows 10Pro operating system. The
132 flow sensors were placed immediately after the output check valve to measure the pump output

133 directly. The amplitude and beat rates were measured using the flow sensors across six separate
134 channels, two channels per pump. While each pump is comprised of five syringes that are
135 mounted on the same linear actuator, the flow through each channel was individually recorded
136 and analyzed to ensure a consistent flow pattern and output through the channels on the same
137 pump and across all three pumps connected to the same device.

138 **Volumetric Analysis**

139 Although the physiologic rate of CSF production and absorption is still an active area of
140 research, $0.3 \frac{ml}{min}$ is currently accepted as the average or near average CSF production rate in a
141 healthy adult human. A range of $0.01 \frac{ml}{min}$ to $0.7 \frac{ml}{min}$ was tested to evaluate the versatility of the
142 pumps. An arbitrary systole time of 0.3 seconds and a pulsation rate of 100 beats per minute
143 were chosen for these experiments. The accuracy and precision of the pumps' output were
144 evaluated by obtaining a total of 150, one-minute weight measurements of degassed, deionized
145 water across 15 pump channels per volume profile. The density of deionized water was measured
146 and verified before the experiment at 1 gram per 1 milliliter of water at room temperature using a
147 graduated beaker and an analytical balance. A Mettler Toledo AT261 DeltaRange Analytical
148 Balance (Mettler-Toledo, LLC, USA) and Ae Adam Analytical Balance Model AAA 160DL
149 (Adam Equipment Inc, USA) were used for all weight measurements. The flow of information
150 between various components of the system relative to the unidirectional fluidic flow from source
151 to output collection beakers is summarized in Figure 1. To evaluate the volumetric consistency
152 of the pump output, the pumps were set using the user interface to run each volume rate for 10
153 consecutive minutes. The output of each channel was collected and weighed in individual
154 beakers. The pumps were properly cleaned and primed using the built-in feature within the user
155 interface before the experiments.

156 **Amplitude**

157 Due to its implications in diagnostic and clinical applications, peak amplitude remains an
158 important variable that was incorporated into the benchtop model. While the pump net output
159 was solely a function of the distance the plungers were pushed forward, the amplitude of each
160 beat was a multifactorial variable that was a function of pumps' volume rate, beat rate, and the
161 time required for a beat to be completed, analogous to systole time during a regular heart cycle.

162 The amplitude of individual beats was a function of the three variables independently specified
163 within the user interface. According to Equation 1, the amplitude is inversely correlated to
164 systole time and beat rate, while it is directly correlated to pump output volume rate. The
165 dampening factor is a function of the overall compliance and material properties of all the
166 components within the fluidic circuit including syringes, silicone tubes, and valves.

$$167 \quad \blacktriangleright \text{Amplitude} \left(\frac{ml}{min} \right) = \frac{\text{Volume rate} \left(\frac{ml}{min} \right) \times 60}{\text{Systole time (seconds)} \times \text{Heart rate} \left(\frac{Beats}{min} \right)} \times \text{Dampening Factor}$$

168 **Systole Time**

169 Systole time is also an important variable within the domains of diagnostic and clinical
170 applications. Systole time in the benchtop model was representative of the total duration of
171 motor output, or the length of time the motor was in motion analogous to ventricular systole
172 during a regular cardiac cycle. The incorporation of this variable into the benchtop model
173 allowed for accurate control throughout the beat cycle length and inherently, the amplitude
174 characteristics of a certain inputted profile. The manipulation of this variable across different
175 flow profiles did not change the output volume of the profile, because this variable is an operator
176 in the time domain and not in the volumetric output domain. Beat cycle duration was the total
177 length of time for a complete beat cycle which was ideally equal to twice the specified systole
178 time in a setup with no compliance. However, the compliance of silicone tubing, check valves,
179 and residual air bubbles may have an impact on the beat cycle duration.

$$180 \quad \blacktriangleright \text{Beat Cycle Duration (seconds)} \cong 2 \times \text{Systole time (seconds)}$$

181

182 **Tubing and Valve System**

183 One of the main considerations in the early stages of the development of the pump was its
184 compatibility with in-vitro bioreactor projects that often require more separate channels to
185 eliminate cross-contamination between individual samples. Therefore, each channel has a
186 separate input and output 50 cm 3mm inner diameter silicone tube. Two check valves are
187 implemented per channel to allow the syringes to prime and refill automatically. The mechanical
188 inefficiencies of the system were also accounted for within the controlling program. The check

189 valves are also useful in the automatic sterilization process of the pump and tubing system using
190 built-in 20-minute rinse cycles with 99% isopropyl alcohol followed by three deionized water
191 cycles to remove the remaining isopropyl alcohol from the system. Figure 2 shows the pumps
192 from various angles with the CAD models appearing on the left and the assembled pump on the
193 right

194 **Results**

195 The pumps' minimum and maximum output volume rate, beats, and amplitude limits were
196 determined through trial and error. The optimal domain of operation for the pumps is
197 summarized in Table 1. The accepted physiologic range for each category is included to illustrate
198 that the non-pathologic human CSF production falls within the pumps' optimal operation range.
199 It is noteworthy to mention that the mechanical and software limits of the setup were not reached
200 during these experiments. However, the reported values in Table 1 correspond to the domain at
201 which the pumps were at peak performance.

202 **Volumetric Analysis**

203 The mean of 10 1-minute measurements across all fifteen channels for each specified volume
204 rate is reported in Table 2. The highest and the lowest recorded values are also specified as well
205 as the mean absolute error (MAE), in $\frac{ml}{min}$ and the mean relative error in percentage. The
206 measured mean of each output volume rate relative to the specified input is visually represented
207 in Figure 3. The linear regression function with an R^2 value of 0.9998 also indicates the accuracy
208 and precision of the pumps over the optimal domain of operation, 0.01 to $0.7 \frac{ml}{min}$ range.

209 **Independent Variables**

210 A series of tests were performed to validate the pulsatile pump output including the nine
211 experiments depicted in Figures 4,5,6. The flow patterns were collected across 6 channels using
212 Sensirion liquid flow sensors. On the left, the figures illustrate the pump output in 20-second
213 segments while running at different user-specified variables, included below each set of figures.
214 A zoomed-in 1-second interval to better illustrates the unique pattern of individual beats.

215 In the first set of flow patterns, shown in Figure 4, the beat rate and systole time remain constant
216 at $70\left(\frac{\text{Beats}}{\text{min}}\right)$ and 0.1 seconds while the output volume rate varies between 0.35, 0.1, $0.8\frac{\text{ml}}{\text{min}}$.

217 These results indicate that the pumps are capable of variable output regardless of beat rate or
218 systole time.

219 In Figure 5, systole time and output volume rates remained constant at 0.1 seconds and $0.3\frac{\text{ml}}{\text{min}}$
220 while the beat rate changed from $20\left(\frac{\text{Beats}}{\text{min}}\right)$ to $130\left(\frac{\text{Beats}}{\text{min}}\right)$ and $200\left(\frac{\text{Beats}}{\text{min}}\right)$. The number of
221 individual peaks in each 20-second segment in Figures correctly corresponds to the specified
222 beat rate.

223 Finally, in Figure 6, the beat rate is maintained at $70\left(\frac{\text{Beats}}{\text{min}}\right)$ and the output volume rate remain
224 constant at $0.3\frac{\text{ml}}{\text{min}}$ while systole time varies from 0.05 to 0.1 and 0.3 seconds. As illustrated in
225 Figures 2 and Figure 4, the pump can maintain a specified beat rate independent of systole time
226 and volume rate.

227 **Discussion**

228 Using the data acquisition system described earlier, sample flow rates were collected over 20-
229 second intervals to demonstrate the pumps' capabilities in recreating pulsatile flow at
230 physiologically accurate CSF production rates. Variation testing across the three input
231 parameters used to define CSF production rate, those being volume rate, heart rate, and systole
232 time, was also performed to demonstrate the effect of these variables on the subsequent flow
233 pattern. Because of the dampening effects of the tubing and valve system, amplitudes of these
234 flow patterns are reduced across the range of the 20-second interval. Furthermore, zooming in on
235 an individual pulse during the 20-second interval, it is evident that the pump induces an initial
236 rise in flow rate typical to flow patterns recorded during a normal cardiac cycle, followed by a
237 constant reduction in flow rate leading up to the next pulse in the profile.

238 For this study, a consistent silicone tubing setup described earlier was used throughout the
239 testing. The manipulation of this tubing set up in the future and in turn, the dampening factor
240 applied across the individual channels of the pump as well as the pump will not only manipulate
241 the amplitude of each beat within the profile as described by Equation 1 but can also affect the
242 minor spike found on the downward stroke of each beat cycle.

243 The emphasis on the manipulation of the controllable variables of the pump is essential to the
244 success of the pump across many disciplines where accurate tabletop recreations of flow rates
245 and patterns are currently a limiting factor. Specifically for hydrocephalus, the instances
246 presented here recreate the physiologic flow rates and patterns for CSF production which is
247 particularly important as control groups to be compared to the clinical state in future studies.

248 It has been reported that the fluid dynamics of CSF production and absorption are influenced by
249 a broad spectrum of factors such as the individuals' unique anatomy and physical characteristics
250 as well as real-time physiologic conditions such as blood pressure and heart rate [22–25].

251 Furthermore, the input from the central nervous system adds another layer of complexity and
252 variability in CSF dynamics. Therefore, optimal operation over a reasonable range relative to the
253 physiologic conditions was one of the main objectives in the design and development of this
254 device. One of the main advantages of this device over previous models is flexibility in the
255 domain of operation (Table 3). A mean CSF production rate of $0.34 \pm 0.13 \frac{ml}{min}$ was reported by
256 Edsbagge et. al [26]. Profiles at average physiologic heart rate and systole time were used to test
257 the capabilities of the pump recreating the mean reported CSF production rate along with the
258 upper and lower limits of the mean. The domain shown within Table 3 for physiologic CSF
259 production rate has shown to be accurate across its range.

260 The validation of this tabletop model specifically for the use in isolated anatomical subdivisions
261 of human production and absorption system of CSF is limited because of the current difficulties
262 in measuring ICP and CSF flow. However, because of the modular tubing setup of the system,
263 additions to the tube setup in series allow for the easy testing of future components essential to
264 the modern treatment of hydrocephalus and other domains of research such as catheters and
265 valves. The scale of the pump and tubes along with the incorporation of other components such
266 as bioreactor chambers make it a much simpler system to work with within a sterile environment
267 where an incubator and live cells are involved. Furthermore, it has been reported that compliance
268 may have a major physiologic function in CSF flow characteristics and distribution [19,27].

269 Therefore, future studies will also investigate the addition of compliance components to the
270 pump. This study demonstrated that this setup could maintain a CSF production rate, beat rate,
271 and systole time profile for an extended period over 15 channels. However, these variables all
272 change throughout the day not only in hydrocephalic patients but in healthy individuals as well

273 [28–30]. Future iterations of the pump and the controlling program can integrate a system where
274 patient data can be recreated across a full day. The implications of a system like this could alter
275 the perspectives of researchers within this field and other fields where this pump is applicable,
276 where an all-encompassing system may be the new standard in terms of accurate in-vitro testing.

277

278 **Conclusion**

279 In conclusion, the validation of this reciprocating positive displacement pump system allows for
280 the future validation of novel designs to biomaterials and devices used in the treatment of
281 hydrocephalus. Specifically, the use of this system includes major components such as a
282 hydrocephalus catheter and chamber capable of accurately reflecting changes in ventricular
283 expansion, as well as a hydrocephalus valve used to regulate the flow of CSF.

284

285 **Declarations**

286 **Funding:** Research reported in this publication was supported by *the National Institute of*
287 *Neurological Disorders and Stroke of the National Institutes of Health* under award
288 number R01NS094570. Approximately 60% of this project was financed with federal dollars.
289 The content is solely the responsibility of the authors and does not necessarily represent the
290 official views of the National Institutes of Health.

291

292 **Authors' Contributions:**

293 JG: Conceptualization, Methodology, Formal analysis, Investigation, Data curation, Project
294 administration, Writing—original draft, Visualization, and Writing—review & editing.

295 **Acknowledgments**

296

297

298

299 **References**

- 300 1. Orešković D, Klarica M. The formation of cerebrospinal fluid: Nearly a hundred years of
301 interpretations and misinterpretations. *Brain Res Rev.* 2010;64: 241–262.
302 doi:10.1016/j.brainresrev.2010.04.006
- 303 2. Khan MU, Khan B, Ullah W, Ullah A, Ali M. Hydrocephalus: Causes of Hydrocephalus
304 Among Different Age Groups. *Prof Med J.* 2018;25: 1041–1045.
305 doi:10.29309/TPMJ/18.4481
- 306 3. Browd SR, Ragel BT, Gottfried ON, Kestle JRW. Failure of cerebrospinal fluid shunts:
307 Part I: Obstruction and mechanical failure. *Pediatr Neurol.* 2006;34: 83–92.
308 doi:10.1016/j.pediatrneurol.2005.05.020
- 309 4. Shakeri M, Vahedi P, Lotfinia I. A Review of Hydrocephalus. *Neurosurg Q.* 2008;18:
310 216–220. doi:10.1097/wnq.0b013e31817328c9
- 311 5. Achyuta AKH, Stephens KD, Lewis HGP, Murthy SK. Mitigation of reactive human cell
312 adhesion on poly(dimethylsiloxane) by immobilized trypsin. *Langmuir.* 2010;26: 4160–
313 4167. doi:10.1021/la903441u
- 314 6. Greitz D. Radiological assessment of hydrocephalus: New theories and implications for
315 therapy. *Neurosurg Rev.* 2004;27: 145–165. doi:10.1007/s10143-004-0326-9
- 316 7. Khasawneh AH, Alexandra PC, Zajciw PA, Harris CA. intracranial pressure -
317 cerebrospinal fluid production relationships in experimental hydrocephalus. 2020.
318 doi:10.4103/bc.bc
- 319 8. Doron O, Zadka Y, Barnea O, Rosenthal G. Interactions of brain, blood, and CSF: a novel
320 mathematical model of cerebral edema. *Fluids Barriers CNS.* 2021;18: 1–14.
321 doi:10.1186/s12987-021-00274-z
- 322 9. Ringstad G, Vatnehol SAS, Eide PK. Glymphatic MRI in idiopathic normal pressure
323 hydrocephalus. *Brain.* 2017;140: 2691–2705. doi:10.1093/brain/awx191
- 324 10. Qvarlander S, Lundkvist B, Koskinen LOD, Malm J, Eklund A. Pulsatility in CSF
325 dynamics: Pathophysiology of idiopathic normal pressure hydrocephalus. *J Neurol*

- 326 Neurosurg Psychiatry. 2013;84: 735–741. doi:10.1136/jnnp-2012-302924
- 327 11. Román GC, Verma AK, Zhang YJ, Fung SH. Idiopathic normal-pressure hydrocephalus
328 and obstructive sleep apnea are frequently associated: A prospective cohort study. J
329 Neurol Sci. 2018;395: 164–168. doi:10.1016/j.jns.2018.10.005
- 330 12. Jaraj D, Agerskov S, Rabiei K, Marlow T, Jensen C, Guo X, et al. Vascular factors in
331 suspected normal pressure hydrocephalus. Neurology. 2016;86: 592–599.
332 doi:10.1212/WNL.0000000000002369
- 333 13. Enchev Y, Oi S. Historical trends of neuroendoscopic surgical techniques in the treatment
334 of hydrocephalus. Neurosurg Rev. 2008;31: 249–262. doi:10.1007/s10143-008-0131-y
- 335 14. Harris C, Pearson K, Hadley K, Zhu S, Browd S, Hanak BW, et al. Fabrication of three-
336 dimensional hydrogel scaffolds for modeling shunt failure by tissue obstruction in
337 hydrocephalus. Fluids Barriers CNS. 2015;12: 1–16. doi:10.1186/s12987-015-0023-9
- 338 15. Mohammad SA, Osman NM, Ahmed KA. The value of CSF flow studies in the
339 management of CSF disorders in children: a pictorial review. Insights Imaging. 2019;10.
340 doi:10.1186/s13244-019-0686-x
- 341 16. Ziegelitz D, Starck G, Kristiansen D, Jakobsson M, Hultenmo M, Mikkelsen IK, et al.
342 Cerebral perfusion measured by dynamic susceptibility contrast MRI is reduced in
343 patients with idiopathic normal pressure hydrocephalus. J Magn Reson Imaging. 2014;39:
344 1533–1542. doi:10.1002/jmri.24292
- 345 17. McCoy MR, Klausner F, Weymayr F, Georg L, Broussalis E, Golaszewski SM, et al.
346 Aqueductal flow of cerebrospinal fluid (CSF) and anatomical configuration of the cerebral
347 aqueduct (AC) in patients with communicating hydrocephalus - The trumpet sign. Eur J
348 Radiol. 2013;82: 664–670. doi:10.1016/j.ejrad.2012.11.032
- 349 18. McAllister JP, Talcott MR, Isaacs AM, Zwick SH, Garcia-Bonilla M, Castaneyra-Ruiz L,
350 et al. A novel model of acquired hydrocephalus for evaluation of neurosurgical treatments.
351 Fluids Barriers CNS. 2021;18: 1–18. doi:10.1186/s12987-021-00281-0
- 352 19. Benninghaus A, Balédent O, Lokossou A, Castelar C, Leonhardt S, Radermacher K.
353 Enhanced in vitro model of the CSF dynamics. Fluids Barriers CNS. 2019;16: 1–11.

- 354 doi:10.1186/s12987-019-0131-z
- 355 20. Mestre H, Tithof J, Du T, Song W, Peng W, Sweeney AM, et al. Flow of cerebrospinal
356 fluid is driven by arterial pulsations and is reduced in hypertension. *Nat Commun.* 2018;9.
357 doi:10.1038/s41467-018-07318-3
- 358 21. Horbatiuk J, Alazzawi L, Harris CA. The flow limiting operator: A new approach to
359 environmental control in flow bioreactors. *RSC Adv.* 2020;10: 31056–31064.
360 doi:10.1039/d0ra05128d
- 361 22. Martin BA, Loth F. The influence of coughing on cerebrospinal fluid pressure in an in
362 vitro syringomyelia model with spinal subarachnoid space stenosis. *Cerebrospinal Fluid*
363 *Res.* 2009;6: 1–18. doi:10.1186/1743-8454-6-17
- 364 23. Devathasan D, Bentley RT, Enriquez A, Yang Q, Thomovsky SA, Thompson C, et al.
365 Development of an In Vitro Hemorrhagic Hydrocephalus Model for Functional Evaluation
366 of Magnetic Microactuators Against Shunt Obstructions. *World Neurosurg.* 2021;155:
367 e294–e300. doi:10.1016/j.wneu.2021.08.048
- 368 24. Bateman GA, Levi CR, Schofield P, Wang Y, Lovett EC. The venous manifestations of
369 pulse wave encephalopathy: Windkessel dysfunction in normal aging and senile dementia.
370 *Neuroradiology.* 2008;50: 491–497. doi:10.1007/s00234-008-0374-x
- 371 25. Hladky SB, Barrand MA. Mechanisms of fluid movement into, through and out of the
372 brain: Evaluation of the evidence. *Fluids Barriers CNS.* 2014;11: 1–32. doi:10.1186/2045-
373 8118-11-26
- 374 26. Edsbagge M, Tisell M, Jacobsson L, Wikkelso C. Spinal CSF absorption in healthy
375 individuals. *Am J Physiol - Regul Integr Comp Physiol.* 2004;287: 1450–1455.
376 doi:10.1152/ajpregu.00215.2004
- 377 27. Gholampour S, Bahmani M. Hydrodynamic comparison of shunt and endoscopic third
378 ventriculostomy in adult hydrocephalus using in vitro models and fluid-structure
379 interaction simulation. *Comput Methods Programs Biomed.* 2021;204: 106049.
380 doi:10.1016/j.cmpb.2021.106049
- 381 28. Loth F, Yardimci MA, Alperin N. Hydrodynamic modeling of cerebrospinal fluid motion

- 382 within the spinal cavity. *J Biomech Eng.* 2001;123: 71–79. doi:10.1115/1.1336144
- 383 29. Stoquart-ElSankari S, Balédent O, Gondry-Jouet C, Makki M, Godefroy O, Meyer ME.
384 Aging effects on cerebral blood and cerebrospinal fluid flows. *J Cereb Blood Flow Metab.*
385 2007;27: 1563–1572. doi:10.1038/sj.jcbfm.9600462
- 386 30. Wilkie KP, Drapaca CS, Sivaloganathan S. A nonlinear viscoelastic fractional derivative
387 model of infant hydrocephalus. *Appl Math Comput.* 2011;217: 8693–8704.
388 doi:10.1016/j.amc.2011.03.115

389

390

391


392

393

394

395

396







397

398 *Figure 1. Schematic diagram illustrating the flow of information and fluids from user input to*
399 *analyzed measurable outcomes*

400

401

402 *Figure 2. Syringe pump unit CAD models on the left. A fully assembled unit with 3D printed*
403 *parts and other components*




404

405 Table 1. Pump optimal domain and relative to the human physiologic range

Category	Minimum	Maximum	Physiologic Range	within the physiologic domain?
Pulsation Rate ($\frac{Beats}{min}$)	1	400	60-240	Yes
Output Volume Rate ($\frac{ml}{min}$)	0.01	5	0.21-0.47	Yes
Amplitude ($\frac{ml}{min}$)	0.05	55		Yes

406



407

408 *Figure 3. Illustrates the expected versus mean of measured volume rate across 15 channels with*
 409 *a linear function showing a regression*

410


411 Table 2. Volumetric analysis results based on weight measured by analytic balances across the
 412 $0.01 \frac{ml}{min}$ to $0.7 \frac{ml}{min}$

Input	Output				
Volume Rate ($\frac{ml}{min}$)	Mean of 15 channels ($\frac{ml}{min}$)	Lowest Value ($\frac{ml}{min}$)	Highest Value ($\frac{ml}{min}$)	Mean Absolute Error ($\frac{ml}{min}$)	Mean Relative Error
0.01	0.011658867	0.009978	0.013428	-0.001658867	16.58867 %
0.1	0.101159533	0.099528	0.10255	-0.001159533	1.15953 %
0.2	0.200437533	0.19741	0.203108	-0.000437533	0.21876 %
0.3	0.299646867	0.29345	0.303303	0.000353133	0.11771 %

0.4	0.402853533	0.39777	0.406293	-0.002853533	0.71338 3 %
0.5	0.500973533	0.49599	0.506528	-0.000973533	0.19470 7 %
0.6	0.600693533	0.59529	0.605413	-0.000693533	0.11558 9 %
0.7	0.700850867	0.68987	0.706133	-0.000850867	0.12155 2 %
Overall mean:				-0.001034283	2.40373 9 %

413


414



415 *Figure 4. Illustrates the flow pattern at different flow rates while systole time and pulsation rate*
 416 *are constant*

417

418





419 *Figure 5. Visual representation of flow pattern at 78,200, and 20 beats per minute while volume*
420 *rate and systole time remained constant*

421

422

423





424 *Figure 6. Visual representation of flow pattern at various systole times while heart rate and*
 425 *volume rate remained constant at $70 \left(\frac{Beats}{min}\right), 0.3 \left(\frac{ml}{min}\right)$,*

426

427 Table 3. Volumetric analysis of pumps running within the mean CSF production rate reported by
 428 Edsbage et. al [26]

Input	Output				
Volume Rate ($\frac{ml}{min}$)	Mean of 15 channels ($\frac{ml}{min}$)	Lowest Value ($\frac{ml}{min}$)	Highest Value ($\frac{ml}{min}$)	Mean Absolute Error ($\frac{ml}{min}$)	Mean Relative Error
0.21	0.209015533	0.202983	0.211548	0.000984	0.471002%
0.34	0.345996	0.33252	0.350533	-0.006	1.733025%
0.47	0.462307	0.45535	0.467528	0.007693	1.664075%
Overall mean:				0.000892	1.289367%

429

430

431

432

433